Core Viewpoint - The company, Guilin Rhine Biotechnology Co., Ltd., is reducing the investment scale of certain fundraising projects and will permanently supplement its working capital with the remaining funds from these projects [2][10]. Fundraising Overview - The company raised a net amount of approximately 961.11 million RMB from a non-public stock issuance, which was approved by the China Securities Regulatory Commission [2]. - The funds were deposited in a dedicated account, and the management of these funds adheres to relevant regulations to ensure proper usage [3]. Fund Management and Usage - As of July 31, 2025, the total balance in the fundraising account was 1.63 million RMB, with a total interest income of approximately 1.48 million RMB [3]. - The company has directly invested approximately 652.66 million RMB into various projects, including 573.96 million RMB for the Stevia Extraction Factory and 78.70 million RMB for the Rhine Natural Health Products Research Institute [3][4]. Project Completion and Fund Reduction - The Stevia Extraction Factory project has met the completion criteria, with a total investment of 573.96 million RMB, leaving a surplus of approximately 36.32 million RMB [7][9]. - The Rhine Natural Health Products Research Institute project has been partially completed, with 78.70 million RMB invested and an estimated remaining payment of 37.08 million RMB [8][9]. Impact of Fund Reduction - The decision to reduce the investment scale and reallocate surplus funds is aimed at enhancing the company's liquidity and financial structure, thereby supporting sustainable development and maximizing shareholder value [10][9]. - The company’s current research and development capabilities are deemed sufficient to support ongoing business operations and future product innovations [9]. Approval Process - The board of directors and the supervisory board have approved the proposal to reduce the investment scale and reallocate surplus funds, which will be submitted for shareholder approval [10][11].